133 related articles for article (PubMed ID: 27562925)
1. Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
Verger E; Rattarittamrong E; Letort G; Raffoux E; Cassinat B; Kiladjian JJ
Leuk Lymphoma; 2017 Mar; 58(3):749-751. PubMed ID: 27562925
[No Abstract] [Full Text] [Related]
2. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation.
Wu YY; Hung HM; Chen TS; Chao TY; Ho CL
Leuk Res; 2008 Nov; 32(11):1783-6. PubMed ID: 18455791
[No Abstract] [Full Text] [Related]
3. Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.
Diamantopoulos PT; Giannakopoulou N; Hatzidavid S; Viniou NA
Oncol Res Treat; 2019; 42(10):532-535. PubMed ID: 31480052
[TBL] [Abstract][Full Text] [Related]
4. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
5. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
6. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.
Ferrer-Marín F; Bellosillo B; Martínez-Avilés L; Soler G; Carbonell P; Luengo-Gil G; Caparrós E; Torregrosa JM; Besses C; Vicente V
J Hematol Oncol; 2013 Sep; 6():68. PubMed ID: 24011025
[TBL] [Abstract][Full Text] [Related]
7. Competing cell clones in myeloproliferative neoplasm.
Al-Kali A; Verstovsek S; Kantarjian H; Luthra R; Cortes J
Blood; 2010 Dec; 116(23):5074-5. PubMed ID: 21127188
[No Abstract] [Full Text] [Related]
8. Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia.
Lin Y; Lin R; Zhou G; Liu Y; Dong W; Cao Y; Xie X; Gu W
J Int Med Res; 2019 Feb; 47(2):1064-1071. PubMed ID: 30616420
[TBL] [Abstract][Full Text] [Related]
9. Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy.
Tokita K; Maki K; Tadokoro J; Nakamura Y; Arai Y; Sasaki K; Eguchi-Ishimae M; Eguchi M; Mitani K
Leukemia; 2007 Jan; 21(1):190-2. PubMed ID: 17122866
[No Abstract] [Full Text] [Related]
10. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
11. [Malignant myelosclerosis ("acute myelofibrosis") developing into acute myeloblastic leukemia. Clinical and pathologic study of a case].
Scolozzi R; Boccafogli A; Cavazzini L; Altavilla G; Marinelli G; Guidoboni CA; Civolani L; Pansini R
Haematologica; 1982 Aug; 67(4):619-24. PubMed ID: 6815021
[No Abstract] [Full Text] [Related]
12. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
13. De novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone.
Portell CA; Sekeres MA; Rogers HJ; Tiu RV
Br J Haematol; 2012 Apr; 157(2):266-7. PubMed ID: 22150289
[No Abstract] [Full Text] [Related]
14. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
15. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
[TBL] [Abstract][Full Text] [Related]
16. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation.
Jurisic V; Pavlovic S; Colovic N; Colovic M
Med Oncol; 2013 Mar; 30(1):398. PubMed ID: 23297051
[No Abstract] [Full Text] [Related]
17. The mutant CALR allele burden in essential thrombocythemia at transformation to acute myeloid leukemia.
Langabeer SE; Haslam K; Elhassadi E
Blood Cells Mol Dis; 2017 Jun; 65():66-67. PubMed ID: 28552475
[No Abstract] [Full Text] [Related]
18. Spontaneous "remission' of agnogenic myeloid metaplasia and termination in acute myeloid leukemia.
Ragni MV; Shreiner DP
Arch Intern Med; 1981 Oct; 141(11):1481-4. PubMed ID: 6945070
[TBL] [Abstract][Full Text] [Related]
19. [Acute myeloid leukemias in elderly patients].
Parovichnikova EN; Savchenko VG
Ter Arkh; 1990; 62(7):148-54. PubMed ID: 2251656
[No Abstract] [Full Text] [Related]
20. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis.
Zhang SJ; Li JY; Zhang JF; Finn J; Lu H; Xu W; Qian SX; Wu HX
Leuk Res; 2009 Aug; 33(8):e116-8. PubMed ID: 19328546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
